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Abstract 
It is possible to measure cough by assessing its severity, frequency, intensity, associated urge 
and its impact on quality of life. Cough severity can simply be assessed with a Visual 
Analogue Scale. Cough frequency can be assessed objectively with cough frequency 
monitors. Validated cough monitors include the Leicester Cough Monitor and the VitaloJAK. 
Cough reflex sensitivity measurement is better used to investigate the mechanisms of action 
of antitussive medications, rather than assessing efficacy. Health-related quality of life 
measures are available to assess the impact of cough; they include the validated Leicester 
Cough Questionnaire and Cough-specific Quality of Life Questionnaire for adult patients. It 
is best to assess cough with a combination of subjective and objective tools, to capture its 
wide-ranging impact.   
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Introduction 
Cough is one of the most common reasons why patients consult their doctor. Cough can lead 
to significant physical, psychological and social morbidity [1]. Adverse symptoms associated 
with cough such as incontinence and pain, absence from work and social embarrassment are 
frequent [2]. Cough should be measured and quantified when objective verification is 
necessary and for assessing the efficacy of therapy [3]. The formal assessment of cough is 
mostly limited to the research setting, since in the clinic most physicians simply ask patients 
about the severity of their cough. However, validated subjective and objective tools are 
available, such as cough frequency monitors and Health-Related Quality of Life (HRQOL) 
questionnaires [4]. This review will focus on recent developments in the assessment of adult 
patients with cough.  
 
Which tool to assess cough? 
The choice depends on the context of the setting. Several components of cough can be 
assessed, which include severity, frequency, intensity, urge and its impact (HRQOL), see 
Figure 1. The most widely used tools assess severity, frequency and HRQOL. In the clinic, 
when the doctor asks the patient about their cough, the impact of cough on the individual can 
easily be overlooked. The 0-10 cough severity rating is one simple measure that could be 
used in a busy clinic. The clinician asks the patient to rate the severity of their cough between 
0 and 10 and this is simple to document within the consultation notes. This may have the 
advantage of giving the clinician a better perspective about the severity of cough and 
facilitate longitudinal observation. Moreover, it improves the communication between 
clinicians about the severity of cough. Another simple, but more formal tool is the cough 
Visual Analogue Scale (VAS), which can be a paper or electronic format. VAS as well as 
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HRQOL questionnaires are the most commonly used outcome measures in research, and can 
easily be applied to clinical practice.  
 
Objective quantification of cough is perhaps more important in the evaluation of antitussive 
therapy. Cough frequency monitors are being increasingly used in clinical trials [5]. The urge 
to cough can be assessed subjectively during spontaneous or induced cough. It has largely 
been assessed in studies investigating mechanisms of cough [6]. Further studies are required 
to investigate the potential of urge to cough as a clinical end-point in the evaluation of 
antitussive therapy. The intensity of cough can be assessed objectively with physiological 
measures such as cough flow, electromyography and oesophageal (thoracic) pressure. Some 
of these techniques are invasive and a continuous ambulatory recording in the patients’ 
environment is not yet possible. Physiological measures of cough are limited to the laboratory 
setting [7].  
 
The concept that the subjective assessment, objective cough challenge and cough counting 
reveal different facets of the clinical cough is important. The interpretation of their findings is 
entirely dependent on the question asked. From the patients’ perspective, subjective 
assessment and impact on HRQOL is important. The number of coughs is not something 
patients report to their physician. Cough counting is however important when evaluating the 
efficacy of an antitussive medication in a clinical trial. They can be useful to demonstrate 
efficacy objectively since subjective measures could potentially be influenced by other 
factors, for example, drugs that act centrally with a potential to affect mood. The relationship 
between the three methodologies has been studied in detail by Faruqi et al [8]. Cough counts 
were only moderately associated with subjective assessments and cough challenge tests. 
Cough counts related marginally better with HRQOL than cough severity VAS. This data 
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suggests the three methods assess different aspects of cough. A combination of subjective and 
objective tools is necessary to assess cough comprehensively but the choice of tools should 
be based on the question being asked.  
 
Cough Severity 
Cough severity can be assessed with the cough VAS, the Cough Severity Score (CSS) and the 
Cough Severity Diary (CSD). Cough VAS is a brief, simple and cost-effective measure of 
cough severity [9]. It is important to ensure that the scale is 100 mm in length, especially 
when electronic scales are used. The scale must be closed at both ends with perpendicular 
lines, and the wording at the extremes of the scale must be stated outside the scale. An 
example of a cough VAS is given in Figure 2. VAS has not been validated by the rigorous 
methodology applied to other subjective measures, such as HRQOL questionnaires. In the 
author’s opinion, reliability, repeatability and responsiveness are likely to be very good, but 
this requires formal investigation. The minimal clinically important difference (MID) of the 
VAS in acute cough has been reported to be 17 mm [10].  
The Cough Severity Score (CSS) is another subjective tool. It is a two-part question relating 
to cough symptoms during the day and night [11]. The response scale captures some aspects 
of cough frequency, intensity and overall impact. The CSS still requires further validation 
and its MID has not been reported. The Cough Severity Diary (CSD) is a seven-item 
questionnaire that asks patients about the severity, intensity and impact on quality of life [12]. 
There is little published evidence regarding this tool and the MID has not been reported.   
 
Quality of Life Questionnaires 
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There are two HRQOL questionnaires widely used in the assessment of adult patients with 
cough. The Leicester Cough Questionnaire (LCQ) is a nineteen-item questionnaire that 
comprises of three health domains; physical, psychological and social [13]. It has been 
evaluated in patients with chronic and acute cough, post-infectious sub-acute cough, 
bronchiectasis and chronic obstructive pulmonary disease (COPD) [10, 14-17]. The LCQ has 
been well validated. Its internal consistency, repeatability and responsiveness have all been 
reported [13, 18, 19] and the MID is 1.3 and 2.0 in chronic and acute cough respectively [10, 
19]. The LCQ has been used in clinical trials as an outcome measure [20, 21]. The Cough-
specific Quality of Life Questionnaire (CQLQ) is another well-validated HRQOL 
questionnaire [22]. This tool was developed in the United States and consists of twenty-eight 
items allocated to six domains. The CQLQ has been validated in acute and chronic cough. Its 
internal consistency, repeatability and responsiveness have been reported. The MID is 13 
units in chronic cough [23]. The CQLQ has also been utilised in clinical trials evaluating 
antitussive therapies [24].  
 
Objective Cough Frequency Monitoring 
For the objective assessment of cough frequency, there are two tools currently in use in 
clinical trials, the Leicester Cough Monitor (LCM) and the VitaloJAK. They are both 
ambulatory and measure cough in the patient’s own environment. The LCM is an automated 
monitor [25-27]. It consists of an MP3 recording device and a lapel microphone. It can record 
up to four days continuously and it is practical for large-scale, multi-centre studies due to its 
automated capability. The cough detection software is based on the Hidden Markov model, a 
method used in speech recognition. The LCM detects cough events whether occurring in 
isolation or in a bout. The LCM has been validated [5, 25, 28] and utilised in patients with 
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chronic cough, acute cough and COPD [10, 28]. This tool has been used to evaluate 
antitussive therapies in randomised clinical trials [21].  
The VitaloJAK also consists of an MP3 recording device, but has two microphones, a contact 
and a lapel microphone [29]. It can record patients for 24 hours in an ambulatory setting. In 
contrast with the LCM, cough is counted by trained technician from condensed recordings. 
The VitaloJAK has been validated, and been used in patients with acute cough, chronic cough 
and COPD. It has also been used to evaluate antitussive therapy in clinical trials [30, 31].  
 
Cough Reflex Sensitivity Challenge Tests 
The sensitivity of the cough reflex can be evaluated by numerous tussive agents, most 
commonly capsaicin and citric acid. Other tussive agents available include fog, low chloride 
solutions, bradykinin, prostaglandin E2, mannitol and cinnamaldehyde. The most widely used 
methodology is sequential single breath inhalations with a dosimeter to establish the 
concentration of tussive agent causing two and five coughs (C2 and C5 respectively) [32, 33]. 
Cough reflex challenge tests are valuable tools to study pharmacokinetics and interrogating 
cough receptor interaction [34].  The limitations of cough challenge tests are that they cannot 
be used as diagnostic tests because they do not discriminate healthy subjects from patients 
with cough. Additionally they cannot be used to measure the severity of cough as they do not 
reflect symptom burden [35]. Recently, a capsaicin challenge test that involves measuring the 
Emax, which is the maximum cough response evoked by any concentration of capsaicin, has 
been reported to discriminate healthy subjects from those with cough better than the standard 
methodology [36]. An important difference to the standard methodology is that Emax 
involves four inhalations of capsaicin at each dose. Whilst this is a promising development, 
the discrimination between healthy and cough subjects with Emax seems to be applicable 
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only when comparing population means and the discriminative value is likely to be lower 
when evaluating individual patients. Emax needs to be evaluated in larger numbers of 
subjects to confirm the findings of this preliminary study. A tidal breathing method delivering 
capsaicin has also been reported to discriminate patients with cough well from healthy 
controls [37]. C5 was superior than C2 for this purpose. Other methods of performing and 
analysing cough challenge tests should also be explored for diagnostic use. The urge to cough 
following inhalation of capsaicin is a potential method. 
 
Conclusion 
There are numerous validated tools available to assess cough. A combination of subjective 
and objective measures is desirable. In a clinical setting the severity of cough can easily be 
assessed by asking the patient to rate it on a scale between 0-10. In clinical trials of 
antitussive medications objective measures such as cough frequency monitors are being 
increasingly used as primary endpoints. They should always be accompanied by secondary 
outcome measures assessing symptom severity and HRQOL. HRQOL is perhaps the most 
important endpoint from a patient’s perspective. Further work needs to be done to develop 
and evaluate measures of cough intensity and urge to cough.   
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Figure 1. Measuring cough. 
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Figure 2. Cough Severity Visual Analogue Scale.  
 
Please put a cross on the line to indicate the severity of your cough in the past 2 weeks. 
 
 
 
WORST COUGH EVER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO COUGH 
 
 
 
 
Note this scale may not be to size (100 mm). 
 
